Chris W Bodine
CIK 1194405 · Executive Vice President · last filed 2025-10-06
Chris W Bodine is an Executive Vice President who has filed 43 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for ONEW, was dated Apr 22, 2026. Across all open-market trades the lifetime net is −$18.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $28.0M across reported positions. 17 SEC filings were submitted jointly with Actavis plc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CVS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WOONSOCKET, RI 02895
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONEW | Director | 33,928 | $9.49 | $322.0K | $0 | 9 | 2025-10-06 |
| Allergan plc (AGN) Delisted | Director | 0 | — | — | $499.3K | 11 | 2020-05-11 |
| ACT | Director | 12,222 | $48.29 | $590.2K | $0 | 2 | 2015-06-08 |
| Actavis, Inc. (WPI) Delisted | Director | 15,352 | — | — | $0 | 4 | 2012-05-14 |
| CVS | Executive Vice President | 293,003 | $92.53 | $27.11M | -$19.34M | 9 | 2009-02-20 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-22 | ONEW | Notice (144) | −26,036 | -$287.8K | EDGAR |
| 2025-10-06 | ONEW | Grant (A) | +7,892 | $0 | EDGAR |
| 2024-10-03 | ONEW | Grant (A) | +5,228 | $0 | EDGAR |
| 2023-10-03 | ONEW | Grant (A) | +4,880 | $0 | EDGAR |
| 2023-02-27 | ONEW | Grant (A) | +1,661 | $0 | EDGAR |
| 2022-10-04 | ONEW | Grant (A) | +2,491 | $0 | EDGAR |
| 2022-02-24 | ONEW | Grant (A) | +1,866 | $0 | EDGAR |
| 2021-10-04 | ONEW | Grant (A) | +2,487 | $0 | EDGAR |
| 2020-10-05 | ONEW | Grant (A) | +3,660 | $0 | EDGAR |
| 2020-05-11 | Allergan plc (AGN) Delisted | Disp (D) | −18,615 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.